The efficacy of DEB-BACE using Equalshpheres for the treatment of Chemotherapy-fail/Intolerant advanced non-small cell lung cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500108381

Enrollment

Unknown

Registered

2025-08-29

Start date

2025-09-01

Completion date

Unknown

Last updated

2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Receive DEB-BACE using 400 µm EqualSpheres:NA

Receive DEB-BACE using 300-500µm CalliSpheres:NA

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Sign an informed consent form, aged between 18 and 90 years old; 2. Tumor subtype of NSCLC and tumor stage of III B to IV B; 3. Chemotherapy-failure/intolerant NSCLC patients who receive DEB-BACE; 4. ECOG PS 0-3.

Exclusion criteria

Exclusion criteria: 1. Accompanied with other cancers; 2. Estimated survival less than three months; 3. Receive other systemic treatments before progression disease.

Design outcomes

Primary

Measure	Time frame
Progression-free survival;Adverse events;	—

Countries

China

Contacts

Public ContactSheng Xu

Beijing Hospital

xushengir@163.com+86 156 9975 7271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026